This article was originally published in The Gray Sheet
Firms receive $100,000 National Cancer Institute grant to develop a biophotonic non-invasive cervical cancer product. The device uses biophotonic technology to locate cancers and precancers by analyzing light reflected from the cervix. The process distinguishes between normal and cancerous tissue by detecting biochemical and morphological changes at the cellular level. Early clinical studies show that the device detected 31% more cervical precancerous lesions than conventional Pap tests, according to the companies
You may also be interested in...
SpectRx believes that convenience at a lower cost will make its Simple Choice line of diabetes insulin pump disposables, obtained in the Dec. 31, 2001 purchase of Sterling Medivations, more attractive to consumers than competing products
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.